Oncopeptides Announces First Patient Enrollment In Clinical "Window-Of-Opportunity" Study Evaluating Proprietary Peptide Drug Conjugate Platform In Glioblastoma

Loading news article.

Oncopeptides Announces First Patient Enrollment In Clinical "Window-Of-Opportunity" Study Evaluating Proprietary Peptide Drug Conjugate Platform In Glioblastoma | WAPE

Oncopeptides Announces First Patient Enrollment In Clinical "Window-Of-Opportunity" Study Evaluating Proprietary Peptide Drug Conjugate Platform In Glioblastoma

Article summary

Related companies

Comments —